Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for healthcare industry professionals · Wednesday, June 20, 2018 · 452,444,294 Articles · 3+ Million Readers

5-Hydroxytryptamine Receptor 6 - Disease Assessment and Therapeutics Analysis Forecasts to 2024

PUNE, INDIA, March 20, 2018 /EINPresswire.com/ -- WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “5-Hydroxytryptamine Receptor 6 - Pipeline Review, H1 2018”

5-Hydroxytryptamine Receptor 6  

Overview

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 21 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes.

The latest report 5-Hydroxytryptamine Receptor 6 - Pipeline Review, H1 2018, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3066580-5-hydroxytryptamine-receptor-6-5-ht6-or-serotonin

Top Companies mentioned

Avineuro Pharmaceuticals Inc

Celon Pharma SA

Lundbeck AS

Reviva Pharmaceuticals Inc

Suven Life Sciences Ltd

Teva Pharmaceutical

5-Hydroxytryptamine Receptor 6 Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide 5-Hydroxytryptamine Receptor 6    - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for 5-Hydroxytryptamine Receptor 6   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Antagonism of 5-HT6 receptors facilitates dopamine and norepinephrine release in the frontal cortex while stimulation has the opposite effect. 5-HT6 receptor plays an important role in Alzheimer's disease and other forms of dementia and obesity. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 2, 11 and 2 respectively.

5-Hydroxytryptamine Receptor 6 pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

5-Hydroxytryptamine Receptor 6 - Competitive Analysis

Key players are making innovative developments in 5-Hydroxytryptamine Receptor 6 industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of 5-Hydroxytryptamine Receptor 6.

The pipeline guide reviews pipeline therapeutics for 5-Hydroxytryptamine Receptor 6 by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in 5-Hydroxytryptamine Receptor 6 therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates 5-Hydroxytryptamine Receptor 6 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for 5-Hydroxytryptamine Receptor 6.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3066580-5-hydroxytryptamine-receptor-6-5-ht6-or-serotonin

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire